FDA decision: BBP-418 by Ml Bio Solutions Inc. (in 2026)

Kalshi Health › FDA & drugs Closes Dec 31 · $787 traded · $752 at stake · prices read 15 min ago

The odds

91%chance▼ 1

How the odds have moved

Yes: 92% on Oct 19, 91% now.

Each outcome's chance over time on Kalshi. The dots along the bottom are headlines about its subject: point at one to read it.

Every outcome

Outcome	Chance	Day	Bid	Ask	Pays	Contracts
Yes	91%	▼ 1	87¢	94¢	$1.06	869

"Pays" is what a $1 stake returns if that outcome happens, at the price shown (before any fees). Bid and ask are the best prices to sell and buy "Yes".

The news: FDA, Ml Bio Solutions Inc

Search ›

FDA Clinical Investigations: New Guidance on Electronic SystemsThe National Law Review · 25 h agoOn October 2, 2024, the U.S. Food and Drug Administration (FDA) released guidance in a question and answer format regarding the use of electronic systems, electronic records, and electronic signatures in clinical investigations of medical…
Febuxostat Emerges Relatively Unscathed After FDA Advisory Committee ReviewTCTMD.com · 27 h ago(UPDATED) Despite worries over a potential CV risk with febuxostat, there is indeed a population of patients with gout for whom the risk-benefit profile is favorable for the treatment of hyperuricemia, agreed 19 out of 22 panel members at…
FDA investigates Novartis gene therapy link to tumours in childrenEuropean Medical Journal · 14 h agoThe US Food and Drug Administration (FDA) has launched an investigation into a Novartis gene therapy for potential links to tumour growth in patients. The Swiss drug maker disclosed on Friday that two children who had received Zolgensma…
Automated Dry Cleaning, NIR Tech, & FDA Compliancepowderbulksolids.com · 25 h agoTraditional wet cleaning raises bacterial growth concerns. Dry cleaning and NIR technology can offer a safer, FDA-compliant alternative for manufacturers. Automated Dry Cleaning, NIR Tech, & FDA Compliance Hear from an expert how NIR…
Some flea-tick products increase seizure risk in pets, FDA saysWPXI · 14 h agoSome flea and tick drugs could cause seizures and other neurological issues in pets, and owners should consult with their veterinarians to decide on an appropriate treatment, the Food and Drug Administration said. >> Read more trending…
FDA Database Study Differentiates Cutaneous Adverse Events for Liver Cancer TherapiesBIOENGINEER.ORG · 20 h agoA disproportionality analysis of the FDA Adverse Event Reporting System reveals distinct cutaneous toxicity signals between immune checkpoint inhibitors and anti-angiogenic multikinase agents used in liver cancer regimens. News Source…
FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara@PRNewswire · 42 h agoMELBOURNE, Australia and INDIANAPOLIS, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New…
Medtronic Venous Stent Receives U.S. FDA Approval to Treat Venous Outflow ObstructionMedtronic News · 30 h agoMedtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval for the Abre™ venous self-expanding stent... Medtronic Venous Stent Receives U.S. FDA…
Neuren Pharmaceuticals Secures US FDA Orphan Drug Designation for Neonatal Brain Injury TreatmentMarketScreener · 21 h agoNeuren Pharmaceuticals has received orphan drug designation from the US Food and Drug Administration for its drug candidate NNZ-2591, according to a Monday Australian bourse filing. The drug is... Neuren Pharmaceuticals Secures US FDA…
FDA approves additional doses of Trulicity® (dulaglutide) for the treatment of type 2 diabetes@PRNewswire · 25 h agoAWARD-11 showed 3.0 mg and 4.5 mg doses led to additional blood sugar control; as a secondary endpoint, both doses also led to weight loss Sep 03, 2020, 17:12 ET The AWARD-11 trial evaluated the safety and efficacy of additional doses of…
Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant DepressionStock Titan · 14 h agoEdesa Biotech Announces Agreement with KYORIN Pharmaceutical to Develop and Commercialize Paridiprubart in Japan FreeCast Announces Major Partnership with ROKiT Flix to Expand Global Streaming Entertainment Service Qureight’s Fibrosis…
Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure@PRNewswire · 15 h agoJun 24, 2024, 08:15 ET In addition, Cordella enables: Endotronix will launch Cordella in the U.S. later this year. The company also shared that they have submitted a dossier for CE Mark review and expect a decision on European market…

Related markets

All fda & drugs ›

Health › FDA & drugs

When will Compass Pathways submit a NDA for COMP360 psilocybin? (COMP360 psilocybin - NDA)

98%before December

before December98%▲ 6
before 202798%▲ 5
before April 202798%

Health › FDA & drugs

Will the FDA approve retatrutide? (retatrutide (LY3437943))

Dec 9, 2027even chance by

Before Jan 1, 20272%
Before Jul 1, 202712%▼ 9
Before Jan 1, 202856%

2 more

Before Jul 1, 202885%
Before Jan 1, 202990%

Health › FDA & drugs

Will the FDA approve any psychedelic substance for medical use this year? (Before 2027)

16%chance▼ 1

Health › FDA & drugs

When will the FDA reclassify BPC-157 to Category 1?

10%Before 2027

Before 202710%▲ 1

Health › FDA & drugs

When will the FDA approve Compass Pathways' COMP360 Psilocybin? (COMP360 Psilocybin for Treatment-Resistant Depression)

90%Before 2028

Before 202890%▼ 1
Before October 202788%▼ 1
Before July 202787%

2 more

Before Mar 1, 202765%▼ 1
Before Jan 1, 202719%▲ 2

Health › FDA & drugs

FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)

74%chance▼ 1

Odds are traders' prices on Kalshi, Polymarket, ForecastEx and Crypto.com, not forecasts by 4Progressives. Prices read from the venues 4 min ago. Prices may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts. Not betting or investment advice.

About this market

VenueKalshi

Settles onAppliedXL

Trading closesDec 31, 2026 11:59 PM ET

Traded$787 (869 contracts)

At stake$752

Followed here sinceOct 19, 2026

The rules

If the FDA's decision on BBP-418 by Ml Bio Solutions Inc. in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

The full rules are on the market's page at Kalshi.

Reading the odds

A prediction market trades contracts that pay $1 if something happens. Its price is the market's chance: a contract at 62¢ means traders give it 62%. Each number here is the midpoint between the best bid and offer, or the last trade when they are more than ten cents apart.

For a question with many answers (who wins, which range a number lands in), the chances are scaled to add up to 100%. A price ladder ("above 4.25%, above 4.50% ...") gives a whole distribution: its median is where traders see an even chance either way.

Kalshi is a U.S. exchange regulated by the CFTC; its money is counted in contracts, shown here as dollars at their price. Polymarket counts dollars. ForecastEx is Interactive Brokers' exchange, regulated by the CFTC; its contracts too are shown as dollars at their price. Crypto.com lists its markets on Crypto.com | Derivatives North America, a U.S. exchange regulated by the CFTC; it reports the dollars traded. Where more than one asks the same question, each is shown, never averaged.

Prefer betting odds? Switch to American (+150) or decimal (2.50) odds at the top of the page.

Prediction-market prices are what traders pay for each outcome on Kalshi, Polymarket, ForecastEx and Crypto.com, read as the market's implied chance. They are not forecasts by 4Progressives, can move fast and can be wrong; they are read every few minutes and may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts at their price. News comes from the 4Progressives index; prices of stocks, rates and coins from 4Progressives Finance. Nothing here is betting, financial or investment advice. Terms of use. How to use Predictions